Peroxisome proliferator-activated receptor α (PPARα) activates the β-oxidation of fatty acids
in the liver. Fenofibrate is a potent agonist of PPARα and is used in the treatment of …

This study demonstrated that fenofibrate, a lipid-lowering drug, induced a significant time-
dependent cytotoxicity of hepatoma Hep3B cells. Hep3B cells are significantly more …

Glioblastomas are the most aggressive brain tumors for which therapeutic options are
limited. Current therapies against glioblastoma include surgical resection, followed by …

Chemotherapy for colorectal cancer has become more complicated and diversified with the
appearance of molecular‐targeting agents. 5‐Fluorouracil (5‐FU) has been a mainstay of …

Glioblastoma is one of the most aggressive brain tumors. We have previously found up-
regulation of growth differentiation factor 15 (GDF15) in glioblastoma cells treated with the …

Fenofibrate is a fibric acid derivative which exhibits a role of peroxisome proliferator-
activated receptor-alpha agonist. It is widely utilized in therapy of hyperlipidemia and …

Fenofibrate, a peroxisome proliferator-androgen receptor-alpha agonist, is widely used in
treating different forms of hyperlipidemia and hypercholesterolemia. Recent reports have …

PPARα belongs to the peroxisome-proliferator-activated receptors (PPARs) family that
consists of PPARα, PPARδ, and PAPRγ. Activation of PPARα by ligands including fatty acids …

Background Signaling by insulin-like growth factor 1 receptor (IGF-1R) can contribute to the
formation and progression of many diverse tumor types, including glioblastoma. We …

Breast cancer is the most common lethal carcinoma worldwide and better targeted therapies
are still worthy of exploration, having had some great successes already. Abnormal …